Signifier Medical Technologies’ eXciteOSA®, the only FDA-authorized daytime therapy for primary snoring and mild obstructive sleep apnea, demonstrates real-world adherence to treatment of over 80%

21st September 2022

Signifier Medical Technologies Announces Publication of Peer-Reviewed Analysis Demonstrating Improvement in Obstructive Sleep Apnea Severity with Neuromuscular Electrical Stimulation

20th July 2022

Signifier Medical Technologies Announces $49MM Purchase of Existing Shares by Waha Capital, Angelus Sano Ventures and Segulah Medical Acceleration

22nd March 2022

Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technology

26th February 2022

eXciteOSA® Daytime Sleep Apnea Therapy Device Surpasses 50,000 Patient Session Milestone

12th October 2021

Signifier® Medical Receives Prestigious 2020 GOOD DESIGN Award for Superior Design Excellence

1st March 2021

Signifier® Medical Ushers In New Era of Treatment for Sleep Apnea and Snoring with FDA Approval of eXciteOSA® Device

11th February 2021

Signifier® Medical Technologies appoints David Ritscher as Chief Engineer

12th January 2021

Signifier® Medical Technologies Announces Award of UK NHS Supply Chain Tender

22nd December 2020

Signifier® Medical Technologies appoints Alastair Maxwell as Chief Financial Officer

24th November 2020